Psoriasis not only causes physical discomfort to the patient, but more importantly, it affects the appearance of the patient, leading to social stigmatization, etc., which brings a heavy psychological burden to the patient, and the frequency of depression and suicide is also increased. As an autoimmune disease, scientists in this regard hope to develop an effective psoriasis vaccine to solve this problem. And as a pioneer in the field of vaccines, Creative Biolabs is also duty-bound to assume such a responsibility, our vaccine research and development team after ten years of study, made a series of gratifying achievements in the research on psoriasis vaccine.
Development of Psoriasis Vaccines
Monoclonal antibodies are a widely used method for the treatment of non-infectious diseases, but the cost of this method is high. Vaccination is a more economical strategy for preventing infectious diseases or treating chronic diseases that have already occurred. As a disease with a high incidence, the United States spends more than one billion dollars a year on treating psoriasis. In addition, psychological disorders and suicides caused by the disease are also serious social problems. Therefore, it is very urgent and significant to develop effective psoriasis vaccine. Many researchers have achieved certain results in this regard.
Three weeks after immunization with heat-inactivated, delipidated, deglycolipidated Mycobacterium vaccae, two-thirds of the patients improved their condition, but the results of clinical trials on the vaccine were less satisfactory. Another study of non-pathogenic Mycobacterium w has also shown its potential advantages in improving the condition. In addition, patient with severe psoriasis was treated with attenuated live varicella zoster virus, and an improvement in the condition was observed. Although the study was not double-blind, live attenuated varicella zoster virus did improve the patient’s condition compared with the placebo group. In another microbiological-based vaccination strategy, a total of 2,770 people participated in the treatment of psoriasis using leishmania AS100, and the results showed that 68% of patients obtained PASI-75 response. Anti-IL17A monoclonal antibody is highly effective against psoriasis, and a human non-pathogenic plant virus VLP (CMVTT) containing a tetanus toxoid T cell stimulating epitope maintains self-assembly and long-term stability. Thus, a vaccine is constructed by conjugating mouse IL17A to the CMVTT and high levels of anti-IL17A IgG antibodies were detected in immunized mice. Moreover, the effect of the vaccine on mice is comparable to that of the anti-IL17A mAb.
As a common and potentially disabling autoimmune disease, psoriasis will cause great harm to the patient’s physiology and psychology, and the society also pays a high cost to treat the disease. Vaccination is an effective strategy with cost-effectiveness. As a leader in vaccine research, Creative Biolabs has conducted in-depth research on the pathogenesis and cases of psoriasis and has tried various therapeutic strategies and accumulated rich and advanced experience. If you are engaged in the development of psoriasis vaccine, we will be your most helpful assistant!